Chemoradiotherapy versus chemotherapy alone for unresected intrahepatic cholangiocarcinoma: Practice patterns and outcomes from the national cancer data base

Vivek Verma, Adams Kusi Appiah, Tim Lautenschlaeger, Sebastian Adeberg, Charles B. Simone, Chi Lin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Current guidelines recommend chemotherapy (CT) with or without radiotherapy (RT) for unresected intrahepatic cholangiocarcinoma (IC). Although there is currently lack of consensus, previous smaller studies have illustrated the efficacy of local therapy for this population. This investigation evaluated outcomes of chemoradiotherapy (CRT) versus CT alone in unresected IC using a large, contemporary national database. Methods: The National Cancer Data Base (NCDB) was queried for primary IC cases (2004-2013) receiving CT alone or CRT. Patients undergoing resection or not receiving CT were excluded, as were those with M1 disease or unknown M classification. Logistic regression analysis ascertained factors associated with CRT administration. Kaplan-Meier analysis evaluated overall survival (OS) between both groups. Cox proportional hazards modeling assessed variables associated with OS. Results: In total, 2,842 patients were analyzed [n=666 (23%) CRT, n=2,176 (77%) CT]. CRT was less likely delivered at community centers, in more recent time periods (2009-2013), to older patients, and in certain geographic locations. Median OS in the CRT and CT groups were 13.6 vs. 10.5 months, respectively (P<0.001). On multivariate analysis, poorer OS was associated with age, male gender, increased comorbidities, treatment at a community center, and treatment at earlier time periods (2004-2008) (P<0.05 for all). Notably, receipt of CRT independently predicted for improved OS (P<0.001). Conclusions: As compared to CT alone, CRT was independently associated with improved survival in unresected IC. These findings support a randomized trial evaluating this question that is currently accruing.

Original languageEnglish (US)
Pages (from-to)527-535
Number of pages9
JournalJournal of Gastrointestinal Oncology
Volume9
Issue number3
DOIs
StatePublished - Jun 1 2018

Fingerprint

Cholangiocarcinoma
Chemoradiotherapy
Databases
Drug Therapy
Survival
Neoplasms
Geographic Locations
Kaplan-Meier Estimate
Comorbidity
Radiotherapy
Therapeutics
Multivariate Analysis
Logistic Models
Regression Analysis
Guidelines

Keywords

  • Chemoradiotherapy (CRT)
  • Chemotherapy (CT)
  • Intrahepatic biliary cancer
  • Intrahepatic cholangiocarcinoma (IC)
  • Radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Chemoradiotherapy versus chemotherapy alone for unresected intrahepatic cholangiocarcinoma : Practice patterns and outcomes from the national cancer data base. / Verma, Vivek; Appiah, Adams Kusi; Lautenschlaeger, Tim; Adeberg, Sebastian; Simone, Charles B.; Lin, Chi.

In: Journal of Gastrointestinal Oncology, Vol. 9, No. 3, 01.06.2018, p. 527-535.

Research output: Contribution to journalArticle

Verma, Vivek ; Appiah, Adams Kusi ; Lautenschlaeger, Tim ; Adeberg, Sebastian ; Simone, Charles B. ; Lin, Chi. / Chemoradiotherapy versus chemotherapy alone for unresected intrahepatic cholangiocarcinoma : Practice patterns and outcomes from the national cancer data base. In: Journal of Gastrointestinal Oncology. 2018 ; Vol. 9, No. 3. pp. 527-535.
@article{6f8f9414a8eb4f08907a83780e0483b4,
title = "Chemoradiotherapy versus chemotherapy alone for unresected intrahepatic cholangiocarcinoma: Practice patterns and outcomes from the national cancer data base",
abstract = "Background: Current guidelines recommend chemotherapy (CT) with or without radiotherapy (RT) for unresected intrahepatic cholangiocarcinoma (IC). Although there is currently lack of consensus, previous smaller studies have illustrated the efficacy of local therapy for this population. This investigation evaluated outcomes of chemoradiotherapy (CRT) versus CT alone in unresected IC using a large, contemporary national database. Methods: The National Cancer Data Base (NCDB) was queried for primary IC cases (2004-2013) receiving CT alone or CRT. Patients undergoing resection or not receiving CT were excluded, as were those with M1 disease or unknown M classification. Logistic regression analysis ascertained factors associated with CRT administration. Kaplan-Meier analysis evaluated overall survival (OS) between both groups. Cox proportional hazards modeling assessed variables associated with OS. Results: In total, 2,842 patients were analyzed [n=666 (23{\%}) CRT, n=2,176 (77{\%}) CT]. CRT was less likely delivered at community centers, in more recent time periods (2009-2013), to older patients, and in certain geographic locations. Median OS in the CRT and CT groups were 13.6 vs. 10.5 months, respectively (P<0.001). On multivariate analysis, poorer OS was associated with age, male gender, increased comorbidities, treatment at a community center, and treatment at earlier time periods (2004-2008) (P<0.05 for all). Notably, receipt of CRT independently predicted for improved OS (P<0.001). Conclusions: As compared to CT alone, CRT was independently associated with improved survival in unresected IC. These findings support a randomized trial evaluating this question that is currently accruing.",
keywords = "Chemoradiotherapy (CRT), Chemotherapy (CT), Intrahepatic biliary cancer, Intrahepatic cholangiocarcinoma (IC), Radiation therapy",
author = "Vivek Verma and Appiah, {Adams Kusi} and Tim Lautenschlaeger and Sebastian Adeberg and Simone, {Charles B.} and Chi Lin",
year = "2018",
month = "6",
day = "1",
doi = "10.21037/jgo.2018.01.15",
language = "English (US)",
volume = "9",
pages = "527--535",
journal = "Journal of Gastrointestinal Oncology",
issn = "2078-6891",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "3",

}

TY - JOUR

T1 - Chemoradiotherapy versus chemotherapy alone for unresected intrahepatic cholangiocarcinoma

T2 - Practice patterns and outcomes from the national cancer data base

AU - Verma, Vivek

AU - Appiah, Adams Kusi

AU - Lautenschlaeger, Tim

AU - Adeberg, Sebastian

AU - Simone, Charles B.

AU - Lin, Chi

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Background: Current guidelines recommend chemotherapy (CT) with or without radiotherapy (RT) for unresected intrahepatic cholangiocarcinoma (IC). Although there is currently lack of consensus, previous smaller studies have illustrated the efficacy of local therapy for this population. This investigation evaluated outcomes of chemoradiotherapy (CRT) versus CT alone in unresected IC using a large, contemporary national database. Methods: The National Cancer Data Base (NCDB) was queried for primary IC cases (2004-2013) receiving CT alone or CRT. Patients undergoing resection or not receiving CT were excluded, as were those with M1 disease or unknown M classification. Logistic regression analysis ascertained factors associated with CRT administration. Kaplan-Meier analysis evaluated overall survival (OS) between both groups. Cox proportional hazards modeling assessed variables associated with OS. Results: In total, 2,842 patients were analyzed [n=666 (23%) CRT, n=2,176 (77%) CT]. CRT was less likely delivered at community centers, in more recent time periods (2009-2013), to older patients, and in certain geographic locations. Median OS in the CRT and CT groups were 13.6 vs. 10.5 months, respectively (P<0.001). On multivariate analysis, poorer OS was associated with age, male gender, increased comorbidities, treatment at a community center, and treatment at earlier time periods (2004-2008) (P<0.05 for all). Notably, receipt of CRT independently predicted for improved OS (P<0.001). Conclusions: As compared to CT alone, CRT was independently associated with improved survival in unresected IC. These findings support a randomized trial evaluating this question that is currently accruing.

AB - Background: Current guidelines recommend chemotherapy (CT) with or without radiotherapy (RT) for unresected intrahepatic cholangiocarcinoma (IC). Although there is currently lack of consensus, previous smaller studies have illustrated the efficacy of local therapy for this population. This investigation evaluated outcomes of chemoradiotherapy (CRT) versus CT alone in unresected IC using a large, contemporary national database. Methods: The National Cancer Data Base (NCDB) was queried for primary IC cases (2004-2013) receiving CT alone or CRT. Patients undergoing resection or not receiving CT were excluded, as were those with M1 disease or unknown M classification. Logistic regression analysis ascertained factors associated with CRT administration. Kaplan-Meier analysis evaluated overall survival (OS) between both groups. Cox proportional hazards modeling assessed variables associated with OS. Results: In total, 2,842 patients were analyzed [n=666 (23%) CRT, n=2,176 (77%) CT]. CRT was less likely delivered at community centers, in more recent time periods (2009-2013), to older patients, and in certain geographic locations. Median OS in the CRT and CT groups were 13.6 vs. 10.5 months, respectively (P<0.001). On multivariate analysis, poorer OS was associated with age, male gender, increased comorbidities, treatment at a community center, and treatment at earlier time periods (2004-2008) (P<0.05 for all). Notably, receipt of CRT independently predicted for improved OS (P<0.001). Conclusions: As compared to CT alone, CRT was independently associated with improved survival in unresected IC. These findings support a randomized trial evaluating this question that is currently accruing.

KW - Chemoradiotherapy (CRT)

KW - Chemotherapy (CT)

KW - Intrahepatic biliary cancer

KW - Intrahepatic cholangiocarcinoma (IC)

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=85047526703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047526703&partnerID=8YFLogxK

U2 - 10.21037/jgo.2018.01.15

DO - 10.21037/jgo.2018.01.15

M3 - Article

C2 - 29998018

AN - SCOPUS:85047526703

VL - 9

SP - 527

EP - 535

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

SN - 2078-6891

IS - 3

ER -